New injectable drug hopes to boost heart function in PAH patients
NCT ID NCT07177703
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests whether adding an injectable medication called treprostinil to standard oral therapy can improve heart function in people with intermediate-risk pulmonary arterial hypertension (PAH). About 32 adults will receive the drug for 3 months, with heart scans and walking tests used to measure progress. The goal is to see if the treatment helps the right side of the heart pump more blood.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Treprostinil (injectable medication)
What this could lead to
If it works, this could offer a new treatment option for people with intermediate-risk PAH whose current oral medications aren't enough.
What could go wrong
This is a small, early-phase study with no placebo group, so results may not be conclusive. The injectable drug can cause side effects like pain at the injection site and requires careful dose adjustment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION (PAH) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.